Most of what circulates about Amanita online is rooted in folklore, anecdote, or borrowed from the psilocybin conversation. The science on Amanita muscaria specifically is still young, but the science on muscimol, its principal active compound, is not. Muscimol has been studied for decades as a research tool for understanding the GABA system, and that body of work tells us quite a lot about what this mushroom is doing in the body and brain.
This page is my attempt to consolidate the most relevant and honest research in one place. Google scholar turns up over 52,000 papers that reference "muscimol", so I've onsolidated the best ones here for ease of access. I also distinguish between studies on Amanita muscaria itself and studies on muscimol specifically, because they are not always the same thing and flag where evidence is preliminary, animal-only, or where more human research is needed.
I update this page as new studies are published.
Why Muscimol Research Matters for Amanita Users
Muscimol appears in over 50,000 papers on Google Scholar, not because of Amanita’s popularity, but because it is one of the most direct activators of the GABAa receptor ever identified. Unlike synthetic GABA, it crosses the blood-brain barrier, making it an ideal research compound for studying the brain’s primary inhibitory system. GABA dysfunction has been implicated in anxiety, insomnia, mood, chronic pain, epilepsy, and neurodegeneration. Muscimol research, by extension, is research into all of these.
What makes this relevant to Amanita users is that decarboxylated preparations deliver the same compound being studied in these labs, just at much lower and more gradual doses than most research protocols. The translation is not always direct, but it is closer than it is for most supplements.
Why Study Muscimol Specifically?
Synthetic GABA supplements exist but fail to cross the blood-brain barrier, making GABA nearly impossible to deliver to the brain without invasive procedures. Muscimol solves this, it crosses freely and binds to the GABAa receptor with even greater affinity than our own endogenous GABA, producing a more sustained effect.
What makes muscimol uniquely interesting is where it binds. Most GABAergic substances (like alcohol, benzodiazepines & kava) bind at the allosteric site, a side entrance that amplifies GABA’s effect indirectly. Instead, muscimol binds at the orthosteric site, the main binding pocket where GABA itself docks. This is a fundamentally different mechanism, which is why muscimol produces a different quality of calm than any of these substances and why its interaction profile is much more aligned with the body's neurochemistry than pharmaceuticals.
The Research Landscape
Interest in Amanita has grown sharply in recent years. Google searches rose 114% between 2022 and 2023 alone. With that interest has come a wave of new research: a 2023 systematic review covering 22 studies found muscimol effective at reducing neuropathic pain with effects appearing within 15 minutes. A 2023 paper in Frontiers in Pharmacology examined Amanita extract’s effect on human brain immune cells for the first time. A 2024 animal study found muscimol reduced anxiety and depression-related behaviors in specific brain regions. The research is pointing somewhere meaningful and I am confident that the research will only continue to grow in size and quality.
Amanita as an Entheogen?
Many people refer to Amanita as an entheogen because the mushroom seems to possess a spiritual and consciousness expanding personality. In addition, each person that works with Amanita tends to obtain unique wisdom and healing properties, as if the mushrooms gives them what they need and not what they expect. These properties mean the benefits of this mushroom go beyond chemical pharmacology and into the mystical (or magical). Until we have a better understanding of the inner workings of Amanita, scientific studies are a great starting point.
Feel free to peruse the below studies on Amanita Muscaria and muscimol. I will do my best to update this page as more studies get published.
--------------------
Study Library
--------------------
Anxiety & Stress
Muscimol and conditioned fear (Bhaskaran & Bhatt, 2006 — Journal of Neuroscience)
Muscimol reduced conditioned fear responses in animal models by inhibiting activity in the brain regions responsible for encoding emotional memory. Particularly relevant for anxiety rooted in past experience, not just situational stress.
→ View study
GABAergic botanicals and anxiety (Savage et al., 2017 — Phytotherapy Research)
A systematic review of GABA-modulating plants found consistent evidence that compounds acting on the GABAa receptor reduce anxiety in both animal and human studies. Muscimol works through this same mechanism.
→ View study
Muscimol and anxiety/depression behaviors (2024 animal study)
Microinjection of muscimol into specific limbic brain regions reduced anxiety and depressive behaviors in rodents, adding anatomical specificity to how GABA modulation translates into mood outcomes.
Muscimol and GABA activity (ScienceDirect overview)
A comprehensive overview of muscimol’s action on the GABA system, covering its role in quieting overactive neural firing and restoring inhibitory balance across the central nervous system.
→ View study
Sleep
Muscimol and slow wave sleep (Lancel et al., 1999 — Sleep)
Muscimol increased the duration and depth of slow wave sleep, the most physically restorative stage, while reducing wakefulness and improving sleep consolidation in animal models.
→ View study
Muscimol and REM sleep
Multiple studies found muscimol increases both the number and duration of REM episodes, the stage most associated with emotional processing, memory consolidation, and vivid dreaming.
Muscimol and sleep spindles (Ayoub et al., 2013 — PLoS Biology)
Muscimol increased sleep spindle density, a marker of restorative sleep quality associated with memory consolidation and neuroplasticity.
→ View study
GABA and sleep-wake regulation (2024 review — PMC)
A review confirmed that GABAergic activity in the hypothalamus is central to regulating the sleep-wake cycle, contextualizing why muscimol’s mechanism is so directly relevant to sleep support.
→ View study
Worth noting: muscimol and its synthetic analogue gaboxadol both improve slow wave sleep without suppressing REM, which is a meaningful distinction from benzodiazepines and z-drugs that disrupt SWS even as they improve sleep onset.
Dreaming
There are no formal studies on muscimol and dreaming specifically, though hundreds of people report vivid and lucid dreaming as one of the most consistent effects of working with Amanita. What we do have is an interesting adjacent study showing that facing fears through lucid dreaming may help overcome phobias, which points to the therapeutic potential of the dream state that Amanita seems to reliably deepen.
→ View study on lucid dreaming and fears
Pain
Muscimol and neuropathic pain (Ramawad et al., 2023 — systematic review)
A 2023 systematic review of 22 studies found muscimol effective at reducing neuropathic pain, with effects appearing within 15 minutes and lasting at least three hours. The authors suggest muscimol’s selective binding to GABAa receptor subtypes may offer a pathway for targeted pain therapy with fewer side effects than existing pharmaceutical options.
→ View study
Amanita polysaccharides and inflammatory pain (Ruthes et al., 2013 — Carbohydrate Polymers)
Polysaccharide compounds isolated from Amanita muscaria showed potent inhibition of inflammatory pain in animal models, suggesting the full mushroom contains active anti-inflammatory compounds beyond muscimol alone.
→ View study
Muscimol and systemic inflammation (2022 animal study)
Muscimol was shown to protect against systemic inflammatory responses in animal models, adding to evidence of a broader anti-inflammatory profile.
→ View study
Brain Health & Neuroprotection
Amanita muscaria extract and neuroprotection (Dushkov et al., 2019 — Food and Chemical Toxicology)
A standardized muscimol-rich Amanita extract showed statistically significant neuroprotective effects across multiple in vitro neurotoxicity models, including antioxidant and free radical scavenging activity, without inhibiting MAO-B, an important safety marker.
→ View study
Muscimol and Alzheimer’s disease (Fu et al. / PubMed, 2018)
Very low doses of muscimol improved spatial memory and reduced neuroinflammatory markers in rat Alzheimer’s models, normalizing GABA synthesis enzymes and reducing acetylcholine breakdown, two pathways disrupted in the disease.
→ View study
Muscimol and Parkinson’s disease (Levy et al., 1999 — Neurology)
Muscimol microinjections into the subthalamic nucleus reversed Parkinsonian motor symptoms in a small human study, one of the few direct human applications of muscimol in a clinical context.
→ View study
Muscimol and essential tremors
Multiple studies found muscimol suppressed essential tremor without impairing speech or coordination via its inhibitory effects on cerebellar and thalamic circuits involved in tremor generation.
→ View overview
Muscimol and stroke / cerebral ischemia (Lyden & Lonzo, 1994; Bhatt et al., 1993)
Multiple studies through the 1990s established muscimol as neuroprotective in stroke models, protecting the cortex, hippocampus, striatum, thalamus, and substantia nigra from ischemic damage. Combining muscimol with an NMDA antagonist produced enhanced protection compared to either alone, addressing both arms of the excitotoxic cascade that causes neuronal death after stroke.
→ View study
Amanita muscaria and neuroinflammation (Wagner et al., 2023 — Frontiers in Pharmacology)
The first study to examine Amanita extract’s effect on human microglia, the brain’s resident immune cells. The authors note that the whole mushroom’s chemical complexity produces effects beyond muscimol alone, which supports the whole-mushroom argument over synthetic isolates.
→ View study
Mood
Muscimol and serotonin (König-Bersin et al., 1970 — Psychopharmacologia)
Muscimol increased serotonin concentrations in the brain while reducing catecholamines like epinephrine and norepinephrine, consistent with mood stabilization and nervous system calming.
→ View study
Muscimol and dopamine (PubMed, 1981)
At low doses, muscimol modulates dopamine activity in the brain’s reward circuits, relevant to motivation, presence, and sense of wellbeing.
→ View study
Epilepsy
Muscimol and anticonvulsant activity (Dray & Straughan, 1976 — Neuropharmacology)
Muscimol demonstrated anticonvulsant effects in rat seizure models, delaying onset of convulsions and abolishing tonic extension in several seizure types. Potency ranked as diazepam > muscimol > phenobarbital > phenytoin.
→ View study
Phase 1 human clinical trial for drug-resistant epilepsy (Heiss et al., 2019 — Neurosurgery / NIH)
An NIH-funded trial delivered muscimol directly into epileptic brain tissue in patients with drug-resistant epilepsy, establishing 24-hour safety in humans and observing seizure reduction in one of three patients. The most rigorous direct human study of muscimol to date.
→ View study
Addiction & Substance Use
Muscimol and cocaine self-administration (Asin & Wirtshafter, 1985)
Animal studies found muscimol reduced cocaine self-administration in rats via its inhibitory effect on the ventral tegmental area and downstream modulation of dopamine in the nucleus accumbens, the brain’s central reward circuit.
Muscimol and nicotine dependence (Corrigall et al., 2000 — Psychopharmacology)
GABA agonists including muscimol substantially reduced nicotine self-administration in rats when delivered into the VTA, more effectively than they reduced cocaine self-administration in the same model. This suggests GABAergic modulation is a particularly important lever for nicotine addiction specifically.
→ View study
Large-Scale Observational Research
Microdosing with Amanita Muscaria (Baba Masha, 2022)
A two-year observational study with 5,900 participants documented self-reported outcomes from Amanita microdosing. Key findings: 92% reported positive overall outcomes, 79% reported improvement in depression and low energy, 73% reported improved sleep, and 88% reported increased energy and vitality. Not a controlled clinical trial, but the largest human dataset on Amanita microdosing that exists.
I break down all the results of this study in the blog post "Summary of Baba Masha’s Book: Microdosing Amanita Muscaria?"
Peer-reviewed microdosing case study (Turkia, 2024 — ResearchGate)
A peer-reviewed retrospective case study followed a woman microdosing Amanita for 3.5 months for depression, anxiety, and sleep disorders. All symptoms reduced meaningfully, no adverse effects were reported, and liver function tests showed slight improvement rather than deterioration.
→ View study
Where the Research Stands
Muscimol is pharmacologically well-characterized, with a strong mechanistic basis for the sleep, anxiety, pain, and neuroprotective effects people are reporting. Amanita muscaria as a whole-mushroom preparation is less studied, though that is beginning to change. What we do not yet have is a randomized controlled trial of oral Amanita microdosing in humans. That is the gap. Knowing that is what allows you to move forward with real informed consent.
-----
Last updated: 2026. Know of research I missed? Reach out at tara@luminita.co
